|

Vivos Therapeutics, Inc. (VVOS) reports Q3 loss, beats revenue estimates

Vivos Therapeutics, Inc. (VVOS) reports Q3 loss, beats revenue estimates

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +76.67%. A quarter ago, it was expected that this company would post a loss of $0.42 per share when it actually produced a loss of $0.31, delivering a surprise of +26.19%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Vivos Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $6.41 million for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 17.15%. This compares to year-ago revenues of $6.78 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Vivos Therapeutics shares have lost about 95.2% since the beginning of the year versus the S&P 500's gain of 10.5%.

What's next for Vivos Therapeutics?

While Vivos Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Vivos Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.20 on $6.02 million in revenues for the coming quarter and -$1.30 on $21.79 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Veeva Systems (VEEV), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended October 2026. The results are expected to be released on December 3.

This provider of cloud-based software services for the life sciences industry is expected to post quarterly earnings of $2.33 per share in its upcoming report, which represents a year-over-year change of +14.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Veeva Systems' revenues are expected to be $933.79 million, up 15.1% from the year-ago quarter.


Want the latest recommendations from Zacks Investment Research? Download 7 Best Stocks for the Next 30 Days. Click to get this free report

Author

Zacks

Zacks

Zacks Investment Research

Zacks Investment Research provides unbiased investment research and tools to help individuals and institutional investors make confident investing decisions. 

More from Zacks
Share:

Editor's Picks

AUD/USD sits at fresh 10-month lows, nears 0.6700

AUD/USD refreshes ten-month lows below 0.6750 and approaches 0.6700 in Wednesday’s Asian session. Fed rate-hike bets, along with fresh exchange of fire between the US and Iran, underpin the safe-haven US Dollar. Furthermore, the RBA’s dovish tilt weighs on the Aussie and the pair.

USD/JPY defends bids near 159.50 on hawkish BoJ Ueda

USD/JPY is defending bids near 159.50 in the Asian session on Wednesday, holding a three-day losing streak after hawkish commentary from BoJ Governor Ueda supports the Japanese Yen amid looming intervention risks. Meanwhile, escalating Middle East tensions revive US Dollar demand amid hawkish Fed bets, which could limit the pair's downside.



Gold stays deep in red below $3,800; Fed Minutes eyed

Gold sticks to intraday losses below the $3,800 mark in the European session on Wednesday, trading close to its lowest level since September 2025. Following last week’s hot US inflation reports, several Federal Reserve officials adopted a more hawkish tone and signaled further interest-rate hikes. Adding to this, Tuesday’s upbeat US data cemented market bets, which continue to act as a tailwind for the US Dollar, and drive flows away from non-yielding bullion.

Bitcoin stalls as ETF outflows mount ahead of Fed Minutes

Bitcoin stalls near $65,000 on Wednesday as buyers struggle to sustain a recovery from last week’s decline toward $62,000. Weakening institutional demand so far this week from BTC spot Exchange Traded Funds continues to weigh on sentiment.

Nvidia offers up double beat in third quarter

Nvidia (NVDA) shares jumped 3% afterhours as the leading AI chipmaker easily surpassed Wall Street's projections for the third quarter. The semiconductor powerhouse posted adjusted earnings per share of $2.68, 8.5% or $0.21 better than the consensus. Revenue of $115.85 billion clobbered the consensus by $7.1 billion or 6.6%.

Gold isn't being sold for thew reason most people think
Gold (XAU/USD) remains under heavy selling pressure on Monday, hitting its lowest level in 13 months. The precious metal is struggling to recover despite escalating geopolitical tensions in the Middle East, a backdrop that would normally encourage investors to seek protection in safe-haven assets. However, the main driver behind Gold's decline is not the geopolitical uncertainty itself.